共 35 条
- [2] [Anonymous], 2023, HIV in the US | HIV Statistics Center | HIV | CDC
- [3] [Anonymous], 2024, LATITUDE Phase III Interim Trial Data Indicates ViiV Healthcare's Long-Acting Injectable HIV Treatment Cabenuva (Cabotegravir + Rilpivirine) Has Superior Efficacy Compared to Daily Therapy in Individuals Living with HIV Who Have Adherence Challenges | GSK
- [7] CDC, HIV Surveillance Supplemental Report 20202020
- [9] Are Patients and Their Providers Talking About Long-Acting Injectable Antiretroviral Therapy? Penetration into Clinical Encounters at Three US Care Sites [J]. OPEN FORUM INFECTIOUS DISEASES, 2022, 9 (07):
- [10] Acceptability and preferences for long-acting antiretroviral formulations among people with HIV infection [J]. AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2021, 33 (06): : 801 - 809